Berlin

• A bioavailability study of epinephrine following a single dose of emergency response auto-injector in comparison to epinephrine injection in … Ended
  2024-516575-32-00 3 2025-01-10 Allergic reactions (Type 1), including anaphylaxis, idiopathic anaphyl
• First-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTX-PID in healthy male volunteers Ended
  2023-503892-83-00 1 2024-12-27 Healthy volunteers with circulating Neutralising antibodies (NAbs) aga
• A Phase 1 Trial Assessing Pharmacokinetics and Safety of CAM2056 (Semaglutide Subcutaneous Depot) Ended
  2024-518040-21-00 1 2024-12-18 Body weight management
• Effects of AZD5004 in adults who are living with obesity or overweight with at least 1 weight-related medical condition Ended
  2024-513691-18-00 4 2024-12-11 Participants living with Obesity or Overweight with at least 1 comorbi
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-024) Ended
  2024-512278-92-00 4 2024-12-09 Pulmonary Arterial Hypertension (PAH)
• L19IL2/L19TNF in patients with non-melanoma skin cancer. Ended
  2024-518530-92-00 4 2024-12-09 Patients with high-risk, locally advanced (non-metastatic, node negati
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended
  2024-511057-22-00 5 2024-12-04 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy a … Ended
  2024-513104-34-00 4 2024-11-25 Major Depressive Disorder
• An open-label, DDI study to investigate the effects of amlitelimab on the PK of selected cytochrome P450 substrates Ended
  2024-513495-17-00 3 2024-11-20 Dermatitis atopic
• A first-in-human study to investigate safety and tolerability of SAR446959 in participants with osteoarthritis of the knee Ended
  2024-514015-96-00 1 2024-11-20 Osteoarthritis
• Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and … Ended
  2024-517340-61-00 5 2024-11-19 Patients after curative intent resection of cholangiocarcinoma (intrah
• Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN … Ended
  2023-508812-45-00 10 2024-11-11 Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
• A study to assess the effect of gemfibrozil, itraconazole and phenytoin on levels of IPN60250 in the blood of healthy adult participant. Ended
  2024-513891-16-00 3 2024-11-08 Not applicable
• Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat … Ended
  2023-508474-29-00 4 2024-10-30 Dermatitis, Atopic
• A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended
  2023-509197-35-00 5 2024-10-17 Thyroid Eye Disease (TED)
• Efficacy, safety, and dose-response of a Live Biotherapeutic Product (BGY-1601-VT, vaginal tablet) as a first-line monotherapy in women with … Ended
  2023-508958-26-00 7 2024-10-16 Gynaecological
• A Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Influenza Vaccine Compared with a Licensed Influenza … Ended
  2024-516240-26-00 5 2024-10-11 Influenza
• A clinical trial to determine if AIC263029 is safe when dosed only once or several times, and to investigate how it moves within the human b … Ended
  2023-510074-13-00 1 2024-10-02 BKV-associated nephropathy
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511360-87-00 5 2024-10-02 hidradenitis suppurativa (HS)
• Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome Ended
  2023-509638-20-00 4 2024-09-30 Alport Syndrome
• Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dos … Ended
  2023-506000-50-00 4 2024-09-26 Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-H
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511363-28-00 5 2024-09-24 hidradenitis suppurativa (HS)
• An open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of multiple doses of the gastric acid-red … Ended
  2023-506305-18-01 3 2024-09-19 Hereditary angioedema
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in adult participants with severe … Ended
  2024-511225-64-00 4 2024-09-18 Alopecia areata

Showing 1,345–1,368 of 1,776 trials